Source comparison
PT-141 Men Over 40: Dosing Protocol Comparison
The table below compares PT-141 dosing parameters for men under 40 versus men over 40, accounting for the receptor density, clearance rate, and side effect profile differences that emerge with age. Effective Dose Range 1.0–1.5mg subcutaneous 1.75–2.5mg subcuta
This comparison does not assign a generated winner or score.
- The table below compares PT-141 dosing parameters for men under 40 versus men over 40, accounting for the receptor density, clearance rate, and side effect profile differences that emerge with age.
- Effective Dose Range
- 1.0–1.5mg subcutaneous
- 1.75–2.5mg subcutaneous
- Higher dose required due to 12–18% decline in melanocortin receptor density per decade; men with testosterone <400 ng/dL require upper range
- Onset Timing
- 45–60 minutes post-injection
- 90–120 minutes post-injection
- Slower blood-brain barrier transport and reduced receptor availability extend onset; timing variability increases with age
- Duration of Effect
- 6–8 hours
- 4–6 hours
- Shorter duration in older users despite longer systemic half-life. Reflects faster neural clearance of active metabolites
- Nausea Incidence
- 40–50%, resolves in 60–90 min
- 40–50%, resolves in 2–3 hours
- Incidence similar but duration extends due to slower renal clearance; GFR decline of 1 mL/min/year delays peptide elimination
- Blood Pressure Elevation
- +10 mmHg systolic (transient)
- +10–15 mmHg systolic (transient)
- Magnitude similar but risk higher in men >40 due to undiagnosed hypertension prevalence; monitor BP during initial trials
- Injection Site Recommendation
- Abdomen or thigh
- Abdomen preferred
- Abdominal subcutaneous tissue provides faster, more consistent absorption. Critical for older users with extended onset windows